BACKGROUND: The HEmochromatosis and IRon Overload Screening (HEIRS) Study provided data on a racially, ethnically and geographically diverse cohort of participants in North America screened from primary care populations. METHODS: A total of 101,168 participants were screened by testing for HFE C282Y and H63D mutations, and measuring serum ferritin concentration and transferrin saturation. In the present review, lessons from the HEIRS Study are highlighted in the context of the principles of screening for a medical disease as previously outlined by the World Health Organization. RESULTS: Genetic testing is well accepted, with minimal risk of discrimination. Transferrin saturation has high biological variability and relatively low sensitivity to detect HFE C282Y homozygotes, which limits its role as a screening test. Symptoms attributable to HFE C282Y homozygosity are no more common in individuals identified by population screening than in control subjects. CONCLUSIONS: Generalized population screening in a primary care population as performed in the HEIRS Study is not recommended. There may be a role for focused screening in Caucasian men, with some debate regarding genotyping followed by phenotyping, or phenotyping followed by genotyping.
BACKGROUND: The HEmochromatosis and IRon Overload Screening (HEIRS) Study provided data on a racially, ethnically and geographically diverse cohort of participants in North America screened from primary care populations. METHODS: A total of 101,168 participants were screened by testing for HFE C282Y and H63D mutations, and measuring serum ferritin concentration and transferrin saturation. In the present review, lessons from the HEIRS Study are highlighted in the context of the principles of screening for a medical disease as previously outlined by the World Health Organization. RESULTS: Genetic testing is well accepted, with minimal risk of discrimination. Transferrin saturation has high biological variability and relatively low sensitivity to detect HFE C282Y homozygotes, which limits its role as a screening test. Symptoms attributable to HFE C282Y homozygosity are no more common in individuals identified by population screening than in control subjects. CONCLUSIONS: Generalized population screening in a primary care population as performed in the HEIRS Study is not recommended. There may be a role for focused screening in Caucasian men, with some debate regarding genotyping followed by phenotyping, or phenotyping followed by genotyping.
Authors: Roger T Anderson; Nancy Press; Diane C Tucker; Beverly M Snively; Lari Wenzel; Shellie D Ellis; Mark A Hall; Ann P Walker; Elizabeth J Thomson; Ometha Lewis-Jack; Ronald T Acton Journal: Genet Med Date: 2005-10 Impact factor: 8.822
Authors: Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky Journal: N Engl J Med Date: 2005-04-28 Impact factor: 91.245
Authors: A Asberg; K Hveem; K Thorstensen; E Ellekjter; K Kannelønning; U Fjøsne; T B Halvorsen; H B Smethurst; E Sagen; K S Bjerve Journal: Scand J Gastroenterol Date: 2001-10 Impact factor: 2.423
Authors: Lawrie W Powell; Jeannette L Dixon; Grant A Ramm; David M Purdie; Douglas J Lincoln; Gregory J Anderson; V Nathan Subramaniam; David G Hewett; Jeffrey W Searle; Linda M Fletcher; Darrell H Crawford; Helen Rodgers; Katrina J Allen; Juleen A Cavanaugh; Mark L Bassett Journal: Arch Intern Med Date: 2006-02-13
Authors: Emily L Harris; Christine E McLaren; David M Reboussin; Victor R Gordeuk; James C Barton; Ronald T Acton; Gordon D McLaren; Thomas M Vogt; Beverly M Snively; Catherine Leiendecker-Foster; Joan L Holup; Leah V Passmore; John H Eckfeldt; Edward Lin; Paul C Adams Journal: Arch Intern Med Date: 2007-04-09
Authors: Paul C Adams; Mark Speechley; James C Barton; Christine E McLaren; Gordon D McLaren; John H Eckfeldt Journal: Hepatology Date: 2012-04-18 Impact factor: 17.425
Authors: Michael Serhan; David Jackemeyer; Mindy Long; Mark Sprowls; Ismael Diez Perez; Wolfgang Maret; Fang Chen; Nongjian Tao; Erica Forzani Journal: IEEE J Transl Eng Health Med Date: 2020-06-26 Impact factor: 3.316
Authors: Janice L Atkins; Luke C Pilling; Suzy V Torti; Frank M Torti; George A Kuchel; David Melzer Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Barbara de Graaff; Lei Si; Amanda L Neil; Kwang Chien Yee; Kristy Sanderson; Lyle C Gurrin; Andrew J Palmer Journal: Pharmacoecon Open Date: 2017-03